Literature DB >> 8973987

Inverse nonlinear pharmacokinetics of total and protein unbound drug (oxaprozin): clinical and pharmacokinetic implications.

A Karim1.   

Abstract

The nonsteroidal antiinflammatory drug oxaprozin is extensively bound to plasma proteins in a concentration-dependent manner. This study demonstrates for the first time the inverse nonlinear pharmacokinetics of total and unbound oxaprozin and presents clinical implications of this phenomenon. A total of 71 healthy volunteers participated in single- and multiple-dose studies. In study I, 0.6-, 1.2-, and 1.8-gm doses of oxaprozin were given on an empty stomach in a randomized, crossover trial (n = 35). In studies II and III, 1.2- and 1.8-gm doses, respectively, were given once a day for 8 days (n = 12 and 24, respectively). Serial blood samples for total and unbound drug assays were taken over a 240-hour period in study I and for a 24-hour period on days 1, 5, and 8 in studies II and III. After administration of 1.2 gm once daily, steady-state conditions were established by day 5. Actual average steady-state plasma concentrations (Cavg) were lower than those predicted from the single-dose study based on linear kinetics for the total drug, but higher for the unbound drug. Nonlinear changes in Vd/F were also noted with multiple-dose administration. Vd/F increased by 47% for total drug but decreased by 61% for unbound drug relative to single-dose values. Half-lives after single-dose administration for total and unbound drug determined from 24 to 240 hours and from 24 to 72 hours, respectively, were dose independent for total drug, but dose dependent for unbound drug. Half-lives after multiple-dose administration measured from 24 to 48 hours in study II decreased further. In conclusion, oxaprozin clearance for the total drug was increased while that of the unbound drug was decreased after repetitive dosing. This inverse pharmacokinetic behavior has been attributed to the two noncompensatory kinetic effects: concentration-dependent protein binding and saturable metabolism of oxaprozin.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8973987     DOI: 10.1177/009127009603601102

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  4 in total

Review 1.  Choosing the right nonsteroidal anti-inflammatory drug for the right patient: a pharmacokinetic approach.

Authors:  N M Davies; N M Skjodt
Journal:  Clin Pharmacokinet       Date:  2000-05       Impact factor: 6.447

2.  Efficient screening of covariates in population models using Wald's approximation to the likelihood ratio test.

Authors:  K G Kowalski; M M Hutmacher
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-06       Impact factor: 2.745

Review 3.  Clinical pharmacokinetics of oxaprozin.

Authors:  N M Davies
Journal:  Clin Pharmacokinet       Date:  1998-12       Impact factor: 6.447

Review 4.  Free drug metabolic clearance in elderly people.

Authors:  Jennifer M Butler; Evan J Begg
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.